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ABSTRACT
During the last few years many Checkpoint kinase 1/2 (Chk1/Chk2) inhibitors 
have been developed for the treatment of different type of cancers. In this study we 
evaluated the efficacy of the Chk 1/2 inhibitor prexasertib mesylate monohydrate 
in B-/T- cell progenitor acute lymphoblastic leukemia (ALL) as single agent and in 
combination with other drugs. The prexasertib reduced the cell viability in a dose 
and time dependent manner in all the treated cell lines. The cytotoxic activity was 
confirmed by the increment of apoptotic cells (Annexin V/Propidium Iodide staining), 
by the increase of γH2A.X protein expression and by the activation of different 
apoptotic markers (Parp-1 and pro-Caspase3 cleavage). Furthermore, the inhibition 
of Chk1 changed the cell cycle profile. In order to evaluate the chemo-sensitizer 
activity of the compound, different cell lines were treated for 24 and 48 hours with 
prexasertib in combination with other drugs (imatinib, dasatinib and clofarabine). The 
results from cell line models were strengthened in primary leukemic blasts isolated 
from peripheral blood of adult acute lymphoblastic leukemia patients. In this study 
we highlighted the mechanism of action and the effectiveness of prexasertib as single 
agent or in combination with other conventional drugs like imatinib, dasatinib and 
clofarabine in the treatment of B-/T-ALL.
INTRODUCTION
Nowadays the efficacy of conventional treatments for 
adult ALL is still very poor and several leukemia subtypes, 
like the once with complex karyotype or with Mixed Lineage 
Leukemia (MLL) rearrangement, continue to have a very 
poor prognosis due to not adequate treatment [1]. Moreover a 
large percentage of patients initially successfully treated, like 
the Philadelphia-positive ALL patients treated with tyrosine 
kinase inhibitors (TKIs) [2, 3], frequently develop resistance 
to treatment and consequently relapses [4]. Thus, there is a 
need to improve the therapeutic approaches for ALL adult 
patients. Recently, several international research groups 
have focused their studies on the potential effectiveness of 
the inhibition of specific kinases involved in the regulation 
of the cell cycle and in the DNA damage response (DDR) 
pathway [5–7]. In eukaryotic cells, the cell cycle is finely 
regulated by three different checkpoints (G1/S, intra-S 
and G2/M checkpoints) that control the transition from a 
specific phase to another [8]. The G1/S checkpoint is mainly 
controlled by the tumor-suppressor p53 [9] that regulates 
the transition through the G1 phase by enhancing the 
transcription of p21Waf1/Cip1 protein, a cyclin-dependent 
kinase (Cdk) inhibitors [10]. The transition through the 
S and the G2/M phase is regulated by the Chk1 and, at a 
lower rate, by the Chk2. Chk1 and Chk2 are two serine-
threonine kinases involved in the response to DNA damages 
and, in particular, in the response to Single Strand Breaks 
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(SSBs) and Double Strand Breaks (DSBs) of the DNA 
[11]. Numerous stimuli, like Ionizing Radiation (IR), X-ray 
exposure, replicative stress and chemotherapy drugs, activate 
the Chk1/Chk2 response [12]. Chk1 and Chk2 are activated, 
via phosphorylation, respectively by ataxia telangiectasia 
and Rad3-related (ATR) and by ataxia telangiectasia mutated 
protein (ATM) [13–15]. As a consequence of their activation, 
both Chk1/Chk2 arrest the cell cycle, activate DNA damages 
repair or promote cell death via apoptosis if the DNA damage 
cannot be resolved. Although no hereditary mutations 
of Chk1 or Chk2 have been found to promote tumor 
transformation, in numerous types of cancer the expression of 
these kinases have been found altered. In particular in several 
kinds of tumors the over-expression of Chk1 has been related 
to the resistance to treatments and to the increase of genetic 
instability. Due to their biological relevance, numerous 
Checkpoint Kinases inhibitors (Chk-i) have been developed 
in order to potentiate the efficacy of different antineoplastic 
drugs and to increase the cytotoxicity of radiotherapy [16–
24]. Currently although the amount of publications and 
the number of clinical trials regarding the evaluation of 
the efficacy of Chk-i in solid tumor is in constantly growth 
[19, 20], only few studies have been done to demonstrate 
their efficacy in the treatment of hematologic malignancies 
[21] and even a lower number specifically on ALL [22]. 
Our group has recently showed the effectiveness of PF-
0477736, a Chk1/Chk2 inhibitor, in single agent on a panel 
of different B-/T-ALL cell lines and on primary leukemic 
cells isolated from adult B-ALL patients. The results of 
the study showed that Chk1 kinase, but not Chk2, was 
significantly over-expressed in ALL patients in comparison 
to normal mononuclear cells and that the inhibition of Chk1/
Chk2 reduced the cell viability and induced apoptosis on 
primary cells and several cell lines [22]. Starting from this 
background, in this study, we evaluated the in vitro efficacy 
of prexasertib mesylate monohydrate (hereafter referred 
to prexasertib), a novel Chk1/Chk2 inhibitor, in B- and 
T-progenitor ALL as single agent or in combination with 
different drugs like TKIs and other chemotherapy drugs like 
purine nucleoside analogue clofarabine. The prexasertib is 
a small molecule that acts as a selective ATP competitor 
inhibitor of Chk1 and Chk2 [25] proteins. Recently, the 
in vitro/in vivo effectiveness of the compound as a chemo 
sensitizer agent was assessed on different kinds of tumor 
models [26]. Nowadays this molecule is part of a clinical 
phase I study in patients with advance cancer as single agent, 
NCT01115790, and in combination with other chemotherapy 
drugs or radiotherapy (NCT02124148, NCT02555644). The 
chemo-sensitizer activity of the compound was evaluated 
combining prexasertib with different drugs normally 
used in the clinic of adult ALL patients [27]. In particular 
Philadelphia-positive ALL cell lines and primary leukemic 
cells were treated combining prexasertib with two TKIs 
(imatinib and dasatinib). The efficacy of TKIs in single agent 
or in combination with conventional chemotherapy have 
been well established for the treatment of ALL harboring 
the fusion protein BCR-ABL1 [28]. Although recently 
novel specific therapies have been tested for the treatment of 
Philadelphia-negative patients, most of them are still based 
on conventional chemotherapy. Today is crucial to develop 
therapeutic combinations that can increase the effectiveness 
and, simultaneously, reduce the side effects of conventional 
chemotherapies. For this reason Philadelphia-negative cell 
lines and primary cells were treated with prexasertib and with 
the 2’-deoxyadenosine analogue, clofarabine. Clofarabine 
has been showed to induce cell apoptosis due to the reduction 
of nucleoside triphosphate and consequently due to the 
inhibition of ribonucleotide reductase and DNA polymerases 
[29, 30].
RESULTS
Prexasertib inhibits cell viability in B-/T-ALL 
cell lines
The efficacy of the compound, in term of reduction 
of the cell viability, was firstly evaluated on a panel 
of different B-/T-ALL cell lines (BV-173, SUP-B15, 
REH, NALM-6, NALM-19, MOLT-4, RPMI-8402 and 
CCRF-CEM). In order to evaluate the cytotoxicity of 
the compound, the cell lines were incubated for 24 and 
48 hours with increasing concentration of prexasertib 
(1-100 nM). The compound reduced the cell viability 
in all the treated cells in a time and dosage-dependent 
manner. Using specific statistical analysis, the IC
50
 values 
were detected for all the cell lines highlighting the BV-173 
as the most sensitive cell line (6.33 nM) and the REH as 
the less sensitive one (96.7 nM). The sensitivity to the 
compound as single agent did not correlate with leukemia 
cell type (B-ALL vs T-ALL), with the mutational status 
of the tumor-suppressor p53 (BV-173, SUPB-15, NALM-
6 and NALM-19 cells are p53 wild-type whereas REH, 
MOLT-4, RPMI-8402 and CEM cells are p53 mutated) 
(Figure 1A; Table 1) or with the basal expression of 
Chk1 or Chk2 proteins (data not showed). The correlation 
between the mutational status of p53 and the sensitivity 
to the compound was evaluated because of its role in the 
regulation of the G1-S checkpoint and in the response of 
DNA damages [38, 39].
Prexasertib modifies the cell cycle profile in B-/T-
ALL cell lines
In order to evaluate the effects of prexasertib on 
cell cycle progression, different cell cycle analyses were 
performed. Firstly, cells were treated for 24 hours using 
the doses nearest to the IC
50
 values and then stained for 
1 hour with Propidium Iodide (Pi). In agreement with the 
study of King C. and colleagues [26] the treatment with 
prexasertib reduced the amount of cells in G1 and G2/M 
phase while increased the number of cells in S phase. In 
particular, the treatment statistically significant increased 
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Figure 1: Effect of prexasertib on cell viability, induction of apoptosis, inhibition of Chk1 pathway and cell cycle 
profile in B-/T-ALL cell lines. Graphical representation of the IC
50 
values of the B-/T-ALL cell lines after 24 and 48 hours of incubation 
with prexasertib. The IC
50
 values were obtained from two independent experiments A. Cell cycle profile of B-/T-ALL cell lines treated with 
or without prexasertib (IC
50
 value) for 24 hours B. Graphical representation of apoptosis induction by prexasertib. BV-173, NALM-6 and 
REH cells were treated with increasing concentration of drug for 24 and 48 hours C. The blots show, for each cell lines, the expression of 
key elements of the Chk1 pathway after 24 hours of incubation with prexasertib (IC
50
 value) D. In the figure the samples named Control 
were cells treated with 0.1 % of DMSO. In the Western blot analysis the homogeneity of the protein loaded (30 μg) was determined by 
using an internal control (β-actin).
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the number of cells in S phase in SUP-B15 (P-value 
0.0338), NALM-6 (P-value 0.0421), NALM-19 (P-value 
0.0282), CCRF-CEM (P-value 0.0253), MOLT-4 (P-value 
0.0364) and RPMI-8402 (P-value 0.0379) cell lines but 
not in the most sensitive (BV-173: P-value, 0.4616) and 
in the less sensitive (REH: P-value, 0.6424) cell lines 
(Figure 1B). Secondly, the effect of prexasertib on cell 
cycle progression was analyzed treating ALL cell lines for 
different time points. In particular, BV-173, NALM-6 and 
REH cell lines were treated with prexasertib (respectively, 
with 7.5, 30 and 100 nM) for 18, 24, 30 and 48 hours and 
then stained with Pi. In BV-173 and REH cell lines even 
after 48 hours of incubation the amount of cells in S phase 
was not increased by the treatment, on contrary in NALM-
6 cell line the amount of cell in S phase was increased in 
a time-dependent manner (Supplementary Figure S1A).
Prexasertib as single agent activates the 
apoptotic cascade and targets the Chk1 pathway 
in B-/T-ALL cell lines
In order to better investigate the mechanism of 
action of prexasertib and to correlate the inhibition of cell 
viability with the induction of cell death, different Annexin 
V/Propidium iodide (Pi) staining analyses were performed. 
Cells were treated for 24 and 48 hours with increasing 
Table 1: Leukemia sub-type, karyotype, mutational status of p53 and IC
50
 value (after 24 hours) of the panel of B-/T-
ALL cell lines.
CELL LINE LEUKEMIA 
SUBTYPE
KARYOTYPE* MUTATIONAL 
STATUS OF TP53
Prexasertib 
IC
50
(nM)
REH
PH-NEG. 
B-ALL
46(44-47)<2n>X, -X, +16, del(3)(p22), 
t(4;12;21;16)(q32;p13;q22;q24.3)-inv(12)
(p13q22), t(5;12)(q31-q32;p12), der(16)
t(16;21)(q24.3;q22) - sideline with inv(5)der(5)
(p15q31),+18- carries t(12;21) and del(12) 
producing respective ETV6-RUNX1 (TEL-
AML1) fusion and deletion of residual ETC6 
(TEL)
MUT (R181C) 96.7
SUP-B15
PH-POS. 
B-ALL
46<2n>XY, der(1)t(1;1)(p11;q31), add(3)(q2?7), 
der(4)t(1;4)(p11;q35), t(9;22)(q34;q11), add(10)
(q25), ?del(14)(q23q31), der(16)t(9;16)(q11;p13)
WT 61.4
NALM-6
PH-NEG. 
B-ALL
46(43-47)<2n>XY, t(5;12)(q33.2;p13.2) leading 
to ETV6/PDGFRB
WT 36.4
CCRF-CEM T-ALL
90(88-101)<4n>XX, -X, -X, +20, +20, t(8;9)
(p11;p24)x2, der(9)del(9)(p21-22)del(9)(q11q13-
21)x2 - sideline with +5, +21, add(13)(q3?3), 
del(16)(q12)
MUT(R175H,R248Q) 35.3
MOLT-4 T-ALL
89-99<4n>XXYY, +4, +7, +8, +20, +20, del(6)
(q16)x2, der(7)t(7;7)(p15;q11)x2
MUT(R248Q) 21.2
NALM-19
PH-NEG. 
B-ALL
47(45-48)<2n>XY,+5, del(9)(p21.2) WT 19.1
REPMI-8402 T-ALL
90(79-91)<4n>XXX, -X, +3, +3, -10, -13, -14, 
+15, -18, -20, +2mar, dup(4)(q13q23)x2, del(6)
(q14q22)x2, t(11;14)(p15;q11)x2, add(15)(p13) 
- sideline with der(1)t(1;9)(p35/36;q11), add(13)
(q34) - carries t(11;14) with LMO1-TRD@ 
(LMO1-TCRD) rearrangement and cryptic del(1)
(p32) effecting STIL-TAL1 (SIL-TAL1) fusion
MUT(R273C) 8.07
BV-173
PH-POS. 
B-ALL
47(46-48)<2n>X/XY, -9, +22, +mar, add(1)(q42), 
add(8)(p23), t(9;22)(q34;q11), der(22)t(9;22)
(q34;q11), der(?)t(9;?)(?p11;?)
WT 6.33
* Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (Germany), www.dsmz.de
Abbreviations: Ph, Philadelphia; neg, negative; pos, positive; WT, wild-type; MUT, mutated.
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concentration of prexasertib (BV-173 and RPMI-8402: 2, 
7.5 and 15 nM; NALM-6, NALM-19 and MOLT-4: 7.5, 
15 and 30 nM; SUP-B15, REH and CCRF-CEM: 50, 100 
and 200 nM) and the number of apoptotic/necrotic cells 
was evaluated using cytofluorimetry. In line with the results 
from the cell viability assays, the treatment enhanced cell 
death via apoptosis in a time and dosage-dependent manner 
(Figure 1C). The activation of the apoptotic cascade was 
confirmed by immunoblotting as showed by the cleavage 
of the apoptotic marker, poly (ADP-ribose) polymerase 1 
(PARP-1) (Figure 1D). Successively, the results found on 
the cell cycle profile analyses and on the apoptosis analyses 
were correlated with the modifications of the expression of 
different proteins involved in the DDR pathway. To this 
purpose, cells were treated with prexasertib (doses nearest 
to IC
50
 values) for 24 hours and then stained for different 
markers. First of all, to evaluate the on-target activity 
of the compound, samples were stained for phospho-
Chk1ser296, marker of inhibition of the functionality of 
Chk1. In all samples the treatment reduced the amount of 
phospho-Chk1ser296 confirming that Chk1 was specifically 
inhibited by prexasertib. The treatment with prexasertib 
modified the expression of different downstream targets 
of the Chk1/Chk2 pathway most of them involved in 
the regulation of the G2/M checkpoint. In particular, the 
alteration of the number of cells in G2/M phase seen in 
the cell cycle analysis was confirmed by the reduction of 
both basal and phosphorylated isoforms of the phosphatase 
CDC25C (phospho-CDC25Cser216) and of the kinase cyclin-
dependent, CDC2 (phospho-CDC2Tyr15). No significant 
changes have been found on the amount of the basal forms 
of both CDC25A and CDC1. To investigate the effect of 
prexasertib in the induction of DNA damages, cells were 
stained for the following antibodies: phospho-Chk1 ser317 
(marker of activation of the Chk1 pathway), phospho-
Chk2thr68 (marker of activation of the Chk2 pathway), 
γ-H2A.X (marker of induction of DNA damages) and 
Parp-1 (marker of induction of cell death via apoptosis). 
In all the cell lines the induction of DNA damage after the 
treatment was confirmed by increment of both phospho-
Chk1ser317 and γ-H2A.X, while the activation of apoptosis 
was confirmed by the cleavage of Parp-1. The treatment 
changed in a very heterogeneous manner the expression 
of both basal and phosphorylated form of the kinase Chk2 
(phospho-Chk2Thr68). In particular phospho-Chk2Thr68 
was increased in BV-173, NALM-19, RPMI-8402 and 
CCRF-CEM cell lines while decreased in REH, NALM-
6, NALM-19 and MOLT-4. No significant changes have 
been seen on SUP-B15 cell lines after the treatment. The 
effect of the compound on the total amount of Chk2 was 
very heterogeneous among the different cell lines. In all 
the treated cell lines prexasertib reduced the total amount 
of Chk2, with the exclusion of BV-173 and REH cell 
lines in which the treatment did not modify the amount 
of Chk2. Finally in order to highlight if the increment 
of the DNA damages and the activation of the apoptosis 
could be related with the induction of cell death by mitotic 
catastrophe, the expression of the phosphorylated form 
of the histone H3 (phospho-HH3ser10), marker of mitosis, 
was evaluated. The expression of phospho-HH3ser10 was 
reduced in SUP-B15, REH, NALM-6 and NALM-19 
while was increased in MOLT-4 and RPMI-8402 cell 
lines. In BV-173 and CCRF-CEM cell lines no significant 
level of phospho-HH3ser10 was detected (Figure 1D). The 
reduction of the amount of phospho-HH3ser10 on NALM-6 
and REH cell lines was confirmed also by flow cytometry. 
Cells were treated for 18, 24, 30 and 48 hours and then 
co-stained using Pi with a primary conjugated antibody, 
phospho-HH3ser10 (FITC-conjugated). In line with the 
immunoblotting results, the treatment reduced the amount 
of cells positive for the pHH3ser10 in both the cell lines 
(Supplementary Figue S1B). The effect of prexasertib in 
term of protein expression was also analyzed at different 
time points. These experiments highlighted that the effects 
of Chk1 inhibition were time-dependent, especially in term 
of the induction of DNA damages (γ-H2A.X) (Figure S1C). 
The hypothetical mechanism of action of the compound in 
term of perturbation of cell cycle checkpoint functionality 
and in term of progressively accumulation of DNA 
damages is graphically showed in Figure 5.
Prexasertib increases the cytotoxicity of different 
tyrosine kinase inhibitors (TKIs) in philadelphia-
positive cell lines
In order to assess the chemo-sensitizer ability of 
prexasertib, different experiments combining the Chk1/
Chk2 inhibitor with different compounds routinely used 
in the clinic management of ALL were performed. To this 
purpose two Philadelphia-positive cell lines were treated 
for 24 and 48 hours with prexasertib (BV-173 7.5 nM; 
SUP-B15 50 nM) in combination with two different TKIs, 
imatinib (BV-173 500 nM; SUPB15 10 μM) and dasatinib 
(BV-173 50 nM; SUP-B15 500 nM), and the reduction 
of the cell viability was evaluated. In both treated cell 
lines the combinations increased the cytotoxicity of the 
two TKIs respects to the effect of the single treatments 
(Figure 2A). The consequences of the co-treatment, in 
term of change in the expression of different key elements 
of the Chk1 pathway, were investigated using Western 
blot. BV-173 cell line was incubated with prexasertib (7.5 
nM) and with or without the two TKIs (imatinib: 500 nM; 
dasatinib: 50 nM) for 24 hours. The single treatments with 
the TKIs as well as their combinations with prexasertib 
did not significantly change the key elements of the Chk1 
pathway. However in term of induction of DNA damages 
(γH2A.X) the co-treatment resulted in an additive effect 
in both the combinations (Figure 2B). Then to better 
understand the chemo-sensitizer activity of the compound 
and to evaluate the effect of the combination between 
prexasertib and TKIs using sub-toxic concentrations, 
different combination index assays were performed. 
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Figure 2: Effect of prexasertib in combination with TKIs in Philadelphia-positive cell lines. Cell viability analysis of BV-173 
and SUP-B15 cell lines incubated with prexasertib and TKIs (imatinib and dasatinib) for 24 and 48 hours. For each cell lines three different 
experiments have been performed A. The blot shows the expression different proteins of the Chk1 pathway after 24 hours of incubation 
with prexasertib in combination with the two TKIs. The cell line BV-173 was incubated with: prexasertib: 7nM; imatinib: 500nM; dasatinib: 
50nM B. Combination index analysis of BV-173 and SUP-B15 cell lines incubated with increasing concentration of prexasertib (BV-173: 
from 10 to 0.6 nM, dilution rate 1:2; SUP-B15: from 100 to 6.25 nM, dilution rate 1:2) and two increasing concentrations of imatinib (BV-
173: 250 and 500 nM; SUP-B15: 5 and 10 μM) for 24 and 48 hours. The black curve (control) represents the effect of the prexasertib alone 
while the two red curves represent the two combinations (full square prexasertib + 250 nM (BV-173) or +5 μM (SUP-B15) of imatinib; full 
triangle prexasertib + 500 nM (BV-173) or 10μM (SUP-B15) of imatinib). The curves represent the mean of two independent experiments 
C. Normalized Isobologram graphs represent the effect (Combination Index, C.I.) of the combination between prexasertib and imatinib on 
BV-173 and SUP-B15 cell lines after 24 and 48 hours of combination. Each combination is represented in the legend with a specific symbol. 
D. In the figure the samples named Control were cells treated with 0.1 % of DMSO. In the Western blot analysis the homogeneity of the 
protein loaded (30 μg) was determined by using an internal control (β-actin).
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BV-173 and SUP-B15 cell lines were incubated with 
increasing concentration of prexasertib (BV-173: from 0.6 
to 10 nM, dilution rate 1:2; SUP-B15: from 6.25 to 100 
nM, dilution rate 1:2) and two increasing concentration 
of imatinib (BV-173: 250 and 500 nM; SUP-B15: 5 and 
10 μM) for 24 and 48 hours. To clarify the additive or 
synergic effect of the combinations, different isobologram 
analyses were performed. The results of these analyses 
confirmed the synergistic effect of the combination on 
both BV-173 and SUP-B15 cell lines after 24 hours of 
co-treatment (Combination Index = C.I. <1). The synergic 
effect of the combinations was confirmed also after 48 
hours of co-treatment for BV-173 but not for SUP-B15 
cell. Indeed in SUP-B15 cell line only the first three 
combinations showed an C.I. lower than 1 (Figure 2C-2D).
Prexasertib increases the cytotoxicity of 
clofarabine in Philadelphia-negative cell lines
The efficacy as chemo-sensitizer agent of the 
prexasertib on Philadelphia-negative B-/T-ALL cell lines 
was evaluated combining the Chk1/Chk2 inhibitor with 
the purine nucleoside antimetabolite clofarabine, which is 
commonly used in clinical trials for the treatment of young 
and adult ALL patients [31, 32]. The effect of clofarabine in 
term of reduction of the cell viability was evaluated using 
WST-1 reagent and for each cell lines was calculated the 
IC
50
 value (data not showed). The effect of the combination 
was very heterogeneous between the different cell lines 
(Figure 3A). Interestingly no significant differences in 
term of effectiveness of the combination was seen between 
cell lines with p53 mutated, that should have an impaired 
function of the G1/S checkpoint, and with p53 wild type 
(Table 1). To investigate the effect of the combination 
of these two drugs and to evaluate if the cytotoxic effect 
could be dependent on a particular schedule, different 
experiments were performed. For this reason NALM-
6 and REH cell lines were treated respectively with 
clofarabine alone for 48 hours (50 nM), prexasertib alone 
for 48 hours (10 nM), pre-incubated with clofarabine for 
24 hours and then with prexasertib for 24 hours or pre-
incubated with prexasertib for 24 hours and then with 
clofarabine for 24 hours. No significant differences were 
found between the different schedules (Supplementary 
Figure S1C). As with the previous combinations with 
TKIs, the consequences of the combination on the Chk1 
pathway were evaluated using Western blot analysis. REH 
and NALM-6 cell lines were incubated for 24 hours with 
the checkpoint inhibitor in combination with clofarabine 
using for each drug the dose nearest to the IC50 after 24 
hours (clofarabine: 50 nM; prexasertib 100 and 30 nM, 
respectively). The treatment with clofarabine as single 
agent changed the expression of different elements of 
the Chk1 pathway and in particular, the total amount of 
CDC2, CDC25C as well as the phosphorylated form 
of Chk1Ser296 were decreased by the treatment while the 
amount of γ-H2A.X was increased. The combination of 
the two drugs, in both cell lines, additively changed the 
levels of expression of different proteins involved in the 
Chk1 pathway. In particular, the co-treatment increased the 
DNA damages (γ-H2A.X) and the induction of apoptosis 
(Parp-1 and pro-Caspase 3 cleavage) while decreased the 
level of expression of phospho-CDC25Cser216 and phospho-
CDC2tyr15 when compared to the single drugs (Figure 
3B). The ability of prexasertib to sensitize leukemic cell 
lines to the cytotoxicity of clofarabine was evaluated 
performing different combination index analyses. To this 
purpose NALM-6 and REH cell lines were incubated with 
increasing concentration of prexasertib (from 0 to 100 nM 
dilution rate 1:2) and with two different concentrations of 
clofarabine (sub-toxic concentration: 5 and 10 nM ) for 
24 and 48 hours. In REH cell line, with the exclusion of 
the combination between prexasertib 100 nM and 5/10 
nM of clofarabine in which the effect of the combination 
was additive (C.I.=1), the cell viability was synergistically 
reduced (C.I. <1) by the co-treatment. In NALM-6 cell 
lines the cell viability was synergistically reduced in all 
the combinations with the exclusion of two combinations 
(prexasertib 1.56nM and 5 nM of clofarabine; prexasertib 
100 nM and 5/10 nM of clofarabine) in which the effect 
was antagonistic (C.I.>1) (Figure 3C, 3D).
Prexasertib targets the Chk1 pathway on 
leukemic blasts but not on peripheral blood 
mononuclear cell of healthy donors
Finally, the effectiveness of the compound was 
evaluated on different primary leukemic cells isolated 
from the bone marrow and the peripheral blood from 
9 adult B-ALL patients and on the mononuclear cells 
isolated from the peripheral blood from 5 healthy donors. 
To this purpose the primary cells were treated with 
increasing concentration of prexasertib (100, 200 and 
500 nM) for 24 hours and then the reduction of the cell 
viability was evaluated using Trypan blue exclusion dye 
method. Similarly to the results found on B-/T-ALL cell 
lines, prexasertib progressively reduced the cell viability 
in a dose-dependent manner in all the primary leukemic 
cells (Figure 4A). However on the mononuclear cells 
isolated from the healthy donors the treatment did not 
significantly reduce the cell viability (Figure 4B). To 
correlate the reduction of cell viability with the induction 
of DNA damages, the primary cells isolated from the bone 
marrow of 4 adult B-ALL patients were treated with a 
sub-toxic concentration of the compound (100 nM) and 
then stained for phospho-Chk1ser317, Chk1 and γH2A.X. 
The Western blot analysis showed that in all samples, 
although with a high heterogeneity, prexasertib increased 
both markers of DNA damage (phospho-Chk1 ser317and 
γH2A.X) (Figure 4C). By contrast, in normal cells the 
effect of the compound did not reduce significantly the cell 
viability and did not modifie the amount of the different 
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Figure 3: Effect of prexasertib in combination with clofarabine in Philadelphia-negative cell lines. Cell viability analysis 
of Philadelphia-negative ALL cell lines incubated prexasertib and clofarabine for 24 and 48 hours. For each cell lines three independent 
experiments have been performed A. The blots show the expression on NALM-6 and REH cell lines of different proteins of the Chk1 
pathway after 24 hours of treatment with prexasertib in combination with clofarabine. The dosages of each drug have been chosen based 
on the IC
50
 values after 24 hours of incubation B. Combination index assay of NALM-6 and REH cell lines treated with increasing 
concentration of prexasertib (from 1.5 to 100 nM) and sub-toxic concentration of clofarabine (5 and 10 nM). The black curve (Control) 
represents the effect of the prexasertib alone while the two red curves represent the effect of the combinations (full triangle prexasertib + 
5 nM of clofarabine; full square prexasertib +10 nM of clofarabine) after 48 hours of incubation with the two drugs. The curves in graph 
are representative of the mean of two independent experiments C. Normalized Isobologram graphs represent the effect (Combination 
Index, C.I.) of the combination between prexasertib and clofarabine on NALM-6 and REH cell lines. Each combination is represented in 
the legend with a specific symbol D. In the figure the samples named Control were cells treated with 0.1 % of DMSO. In the Western blot 
analysis the homogeneity of the protein loaded (30 μg) was determined by using an internal control (β-actin).
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Figure 4: Effect of prexasertib on primary leukemic cells isolated from adult ALL patients and on peripheral 
mononuclear cells isolated from healthy donors. Cell viability analysis on primary leukemia cells isolated from 9 adult ALL 
patients treated with increasing concentration of prexasertib (100, 200 and 500 nM) for 24 hours. A. Cell viability assay of mononuclear 
cells isolated form the peripheral blood of 5 healthy donors, treated with increasing concentration of prexasertib (100, 200 and 500 nM) 
B. The blot shows the induction of DNA damages on primary leukemic cells isolated from the peripheral blood of 4 newly diagnosed ALL 
patients treated for 24 hours with prexasertib (100nM) C. The blot shows the expression of different proteins of the Chk1 pathways after 
24 hours of incubation with prexasertib (100nM) on the mononuclear cells isolated from the peripheral blood of 5 healthy donors D. Cell 
viability assay of primary leukemia cells isolated from 3 Philadelphia-positive ALL patients treated with prexasertib (100nM) and imatinib 
(5 μM) for 24 hours. The graph represents the main of response to the combination of the three patients E. The blot shows the induction of 
DNA damages on primary leukemia cells isolated from a Philadelphia-positive patient after 24 hours of treatment with prexasertib (100nM) 
in combination with imatinib (5μM) F. In the Western blot analysis the homogeneity of the protein loaded (30 μg) was determined by using 
an internal control (β-actin).
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downstream targets of Chk1 neither increased the amount 
of the phosphorylated form of γH2A.X, with the exclusion 
of one sample (Figure 4D). The chemo-sensitizer ability 
of prexasertib was then evaluated also on the primary 
leukemic cells. To assess that, the primary cells isolated 
from 3 Philadelphia-positive ALL patients were treated for 
24 hours with prexasertib (200 nM) in combination with 
imatinib (5 μM). The concomitant treatment showed an 
additive effect in term of reduction of the cell viability in 
comparison with the effect of the single treatment (Figure 
4E). Finally, to correlate the reduction of the cell viability 
to the induction of DNA damage, primary cells from 
one Philadelphia-positive ALL patient were treated with 
prexasertib (100nM) and imatinib (5uM) in combination 
and then analyzed by western blot. The co-treatment 
synergistically increased the amount of γH2A.X and 
additively increased the phosphorylated for of Chk1ser317 
in comparison with the effects of the single treatments 
(Figure 4F).
DISCUSSION
Nowadays, several studies have showed the 
effectiveness of different Chk1/Chk2 inhibitors as 
monotherapy or in combination with chemotherapy drugs 
or radiotherapy for the treatment of different kind of 
tumors [32–38]. The biological hypothesis of these studies 
is that tumor cells can survive to therapy activating the 
DDR and delay the cell cycle progression to prevent lethal 
cell division [20]. Many compounds arrest tumor cells in 
different phases of the cell cycle. For instance, the purine 
nucleoside analogue clofarabine, arrests tumor cells in 
G1/S phase due to the inhibition of DNA synthesis [39]. 
One of the most important regulators of the cell cycle is 
the Checkpoint kinase 1 (Chk1). In BCR/ABL1-positive 
cells the hyper activation of the ATR-Chk1 pathway after 
the exposure with different genotoxic agents has been 
associated with a delay in G2/M progression and thus 
with a possible mechanism of resistance to treatment [40]. 
Sarmento and colleagues found that T-ALL cells over-
express Chk1 and then demonstrated that the aberrant 
expression is necessary for the proliferation and the 
survival of cancer cells [41]. In this study we demonstrated 
that Chk1 functionality is fundamental for the survival 
of B-/T-ALL cell lines and primary cells, and that the 
inhibition of this kinase using, prexasertib, sensitized both 
cell lines and primary cells to the cytotoxicity of different 
compound normally used for the treatment of adult B-/T-
ALL patients. In line with our previous work evaluating 
the efficacy of the Chk1/Chk2 inhibitor, PF-0477736, the 
treatment with prexasertib reduced the cell viability in a 
time and dose-dependent manner in all the treated cell 
lines. The sensitivity to the compound was not correlated 
with the mutational status of p53, with the leukemia sub-
type (Table 1) or with the basal expression of Chk1/Chk2 
(data not shown). To investigate the effect of prexasertib 
on cell cycle regulation and to clarify mechanisms of 
cell death in different cell lines, cell cycle and western 
blots analyses were performed. In several B-/T-ALL cell 
lines the compound reduced the amount of cells G2/M 
phase and increased the percentage of cells in S phase. 
The reduction of the number of cells G2/M phase and the 
increase of cells in S phase together with heterogeneous 
modification of the mitotic marker phospho-Histone H3 
(pHH3ser10) excluded the mechanism of cell death through 
mitotic catastrophe and corroborated the hypothesis 
of King C. and colleagues [26] of the replication 
catastrophe. However in the most sensitive, BV-173, 
and in the less sensitive, REH, cell lines the treatment 
with prexasertib induced DNA damages and reduced the 
cell viability independently to cell cycle modification 
highlighting other mechanisms of cell death that could 
be not connected neither to the mitotic catastrophe nor 
to the replication catastrophe. The single agent efficacy 
of prexasertib showed on the cell lines were confirmed 
on different primary leukemic cells isolated from adult 
B-ALL patients. Although the compound reduced the 
cell viability and increased the DNA damages in all the 
primary cell treated, we could not define any predictive 
factors of response. The idea of interfering with DNA 
damage response pathway in human cancer as a means to 
improve the cytotoxicity of DNA damaging therapies has 
been demonstrated in many pre-clinical studies. Here we 
evaluated the effectiveness of the prexasertib as a chemo-
sensitizer agent for the treatment of ALL. We showed 
that prexasertib sensitized both Philadelphia-positive cell 
lines and primary leukemic cells to the cytotoxic effect of 
the two TKIs, imatinib and dasatinib. The combinations 
(prexasertib+TKIs) not only synergistically reduced the 
cell viability in comparison to the effect of the single 
treatments but also increased the amount DNA damages 
(γH2A.X), confirming the abrogation of the DNA 
damage response and the consequently accumulation of 
DNA damages. Similar results were found on different 
Philadephia-negative cell lines, combining prexasertib 
with the 2’-deoxyadenosine analogue, clofarabine. Finally, 
by assessing different combination schedules between 
prexasertib and clofarabine, we demonstrated that there 
was no significantly difference in term of reduction of the 
cell viability if the DNA damaging agent (clofarabine) was 
added before or after the DDR inhibitor (prexasertib). The 
results showed in this manuscript, in our opinion, are the 
basis for a future evaluation of this compound in clinical 
trials. We have already showed in our previous work [22] 
that Chk1 is over-expressed in ALL cells in comparison 
to the expression in normal tissue. Moreover the over-
expression of this kinase is fundamental for ALL cells to 
sustain the high genetic instability and to proliferate. For 
this reason, we believe that the treatment with prexasertib 
could be a promising strategy to selectively kill cancer 
cells and preserve normal tissue. Moreover, the results 
of the combinatorial studies showed that the inhibition of 
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the DNA damage response (DDR) pathway could be an 
innovative strategy to limit adverse events, by reducing 
the doses needed to reach a sufficient cytotoxic effect, 
and could increase the effectiveness of imatinib, dasatinib 
and clofarabine, by inhibiting the survival of cancer cells 
(Figure 5).
MATERIALS AND METHODS
Leukemia cell lines and primary samples
Human B- (BV-173, SUP-B15, REH, NALM-6, 
NALM-19) and T-ALL (MOLT-4, RPMI-8402, CCRF-
CEM) cell lines were obtained from Leibniz-Institut 
DSMZ-Deutsche Sammlung von Mikroorganismen und 
Zellkulturen GmbH (Germany). Cells were cultured 
in RPMI-1640 medium (Invitrogen, Paisley, UK) with 
1% l-glutamine (Sigma, St. Louis, MO), penicillin and 
streptomycin (Gibco, Paisley, UK) supplemented with 
10%-20% fetal bovine serum (Gibco) in a humidified 
atmosphere of 5% CO
2
 at 37°C. Primary blast cells from 9 
newly B-ALL cases were obtained, upon written informed 
consent, from the bone marrow and the peripheral blood 
by density gradient centrifugation over Lymphoprep 
(Nycomed UK, Birmingham). Mononuclear cells were 
isolated from the peripheral blood of 5 healthy donors. 
Online databases have been interrogated to molecularly 
characterize leukemia cell lines: International Agency 
for Research on Cancer (IARC) TP53 database 
(http://www-p53.iarc.fr/) and the Catalogue of Somatic 
Figure 5: Schematic representation of the effect of prexasertib on leukemic blast after the exposure to different 
genotoxic agent. The left side of the cartoon hypothesizes how leukemic cell could survive to chemotherapy drugs and to other genotoxic 
agent, activating the cell cycle checkpoint and arresting the cell cycle progression. The right side of the cartoon hypothesizes the mechanism 
of action of the compound in enhancing cell death and inducing checkpoint override after the exposure to different DNA damaging agents.
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Mutations in Cancer, (COSMIC, http:// http://www.sanger.
ac.uk/genetics/CGP/cosmic/).
Drugs and reagents
The Chk1/Chk2 inhibitor prexasertib was provided 
by Lilly Oncology. The purine nucleoside antimetabolite 
(clofarabine) and the tyrosine kinase inhibitors (imatinib 
and dasatinib) were bought by Sigma-Aldrich web site.
Cell viability assay
To evaluate the cytotoxic effect of the treatment 
with prexasertib, B- and T-All precursor leukemia cell 
lines were seeded in 96-well plates at 50,000 cell/100 
μl/well with increasing concentrations of drug (1-100 
nM) for 24 and 48 and incubated at 37°C. Cell viability 
was assessed by adding WST-1 reagent (Roche Applied 
Science, Basel, Switzerland) to the culture medium at 
1:10 dilution. Cells were incubated at 37°C and the optical 
density was measured by microplate ELISA reader at λ450 
after 3 hours. The amount of the formazan formed directly 
correlates to the number of metabolically active cells. All 
viability experiments were performed in triplicates and 
repeated in least two separated experiments.
Primary leukemic cells viability assay
To assess the effect of prexasertib on primary 
leukemic blasts, the cells from 9 newly diagnosed 
Philadelphia-positive and Philadelphia-negative ALL 
cases were obtained, upon written informed consent, 
from the peripheral and bone marrow blood samples 
by density gradient centrifugation over Lymphoprep 
(Nycomed UK, Birmingham).Primary cells were seeded 
on a 6 well plates at 500.000 cells/ml and incubated with 
increasing concentration of prexasertib for 24 hours at 
37°C. In ex-vivo primary leukemia cells the effects on 
cell viability was assessed by counting viable and non-
viable cell numbers by the Trypan blue dye exclusion 
method.
Combination index assay
In order to evaluate the effectiveness of prexasertib 
as chemo-sensitizer agents, B-/T-ALL cell lines were 
seeded in 96-well plastes at 50,000 cell/100μl/well with 
increasing concentration of the compound (dilution 
rate 1:2) and increasing concentration of a second drug 
(dilution rate 1:2), for 24 and 48 hours at 37°C. Cell 
viability was assessed using WST-1 (Roche Applied 
Science, Basel, Switzerland). Cells were incubated at 
37°C and the optical density was measured by microplate 
ELISA reader at λ450 after 3 hours. The amount of the 
formazan formed directly correlates to the number of 
metabolically active cells. All viability experiments were 
performed in triplicates and repeated in least two separated 
experiments. The additive, synergistic, and antagonistic 
effect of the combination was evaluated using Compusyn 
Software, using normalized isobologram graph and 
calculating the combination index, C.I.( C.I<1 synergism; 
C.I. =1 additivity; C.I.>1 antagonism).
Annexin V staining of apoptotic cells
To assess the effect of the compound in the induction 
of apoptosis, three different increasing concentrations of 
prexasertib were used to treat cells lines in order to detect 
apoptotic, necrotic and cell debris. Cell lines were seeded 
in 12-well plates at 500,000 cell/1 ml with increasing 
concentrations of drug (NALM-6, NALM-19, MOLT-
4 and CCRF-CEM: 7.5, 15 and 30 nM; BV-173 and 
RPMI8402: 2, 7.5 and 15 nM; SUP-B15 and REH: 50, 100 
and 200 nM) for 24 and 48 hours and incubated at 37°C. 
Following the treatment, cells were harvested and stained 
with Annexin V/Propidium Iodide (PI) according to the 
manufacturer’s instruction (Roche). The percentage of 
Annexin V-PI positive cells was determined within 1 × 104 
cells of the population by flow cytometry (Facs CantoII, 
BD Biosciences Pharmingen, San Jose, California, USA). 
The mean percentage of Annexin V-PI positive cells and 
standard error measurement was calculated from at least 
two separate experiments.
Western blot analysis
All cell lines were plated in 6-well plates at 
500,000 cells/1 ml with increasing concentrations of 
drug for different time points and incubated at 37°C. For 
evaluate the effect of combination of the Chk inhibitor 
with other drugs (imatinib, dasatinib and clofarabine) 
were used as dosage the IC
50
 for the single drug after 24 
hours of treatment. The drugs in the combination were 
added simultaneously. At the end of the treatment, the 
cells were collected and lysate using a specific buffer 
made of KH2PO4 0,1 M (pH 7,5), Igepal 1% (NP-40), 
β-glicerofosfato 0,1 mM and complete protease inhibitor 
cocktail 1X (Roche Diagnostics). For each sample 
30-50 μg of protein were fractioned on Mini-Protean 
TGX stain-free precasted gels, blotted to nitrocellulose 
membranes (Bio-Rad Trans-blot turbo transfer pack) 
and incubated overnight with the following antibodies: 
Chk1 (#2345S), phosphorylated Chk1 (Ser317)(#2344S), 
phosphorylated Chk1(Ser296)(#2349S) and Chk1 
(Ser345)(#2348S), Cdc25c (#4688S), phosphorylated 
Cdc25C (Ser216)(#9528S), Cdc25a (#3652), Cdc2 
(#9112S), phosphorylated Cdc2 (Tyr15)(#4539S), Chk2 
(#2662S), phosphorylated Chk2 (Thr68)(#2661S), 
phosphorylated H2A.X (Ser139) (γ-H2A.X) (#2577S), 
Caspase3 (#9662S), Parp (#9542S),phosphorylated 
Histone 3 (Ser10) from Cell Signaling. Antibody 
for CDK2 (Cdc1)(sc-163) came from Santa Cruz 
biotechnology. Antibody to β-actin came from Sigma 
(St. Louis, MO). Finally all these antibodies were detected 
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using the enhanced chemiluminescence kit ECL (GE) and 
the compact darkroom ChemiDoc-It (UVP).
Cell cycle analysis
The cell lines were seeded in a 24 wells plate at the 
concentration of 500,000 cells/1 ml and treated for 6 and 
24 hours at 37°C. After the right incubation time the cells 
were harvested and washed with cold PBS. After the wash 
the PBS was discarded and the cell were fixed using ethanol 
70% and stored at -20°C for 24 hours. After the fixation 
period the ethanol was removed by one wash in PBS and 
the cells were incubated for 30 minutes at 37°C with the 
staining mix (sodium citrate pH 2.5 100mM, propidium 
iodide 2.5mg/ml, RNAse 10mg/ml and dH2O). The cell 
cycle analysis was conducted using the BD FACS Canto and 
the quantitative analysis using Modfit LT software (Verity).
Phospho-histone H3/propidium Iodide co-
staining
To evaluate the expression of phospho-Histone H3 
(marker of mitosis) different cell lines were treated with 
prexasertib (IC50 after 24 hours). The cell lines were 
seeded at the concentration of 500,000 cell/ml and treated 
for 18, 24, 30 and 48 hours at 37°C. After the right period 
of incubation the cell were harvested, washed twice in 
ice cold PBS and fixed in -20°C with 70% ETOH for 24 
hours. After the right fixation period the cells were washed 
twice with PBS+0.5%Tween 20 and with PBS+0.1% 
BSA. The cells were incubated in darkness with FITC-
conjugated Phospho-HH3 antibody, dilution rate 1:100 
in PBS+0.1%BSA, for 1 hour on ice (Phospho-Histone 
H3 (ser10) Antibody Alexa Fluor 488 conjugate #9708 
Cell Signaling).To remove the exceeded of antibody the 
samples were washed twice in PBS and the fixed for 30 
minutes with -20°C 70%ETOH. After the second fixation 
the cells were washed twice in cold PBS and then stained 
with the staining mix(( sodium citrate pH 2.5 100mM, 
propidium iodide 2.5mg/ml, RNAse 10mg/ml and dH2O) 
for 30 minutes at room temperature. The cell cycle 
analysis and the detection of the phosphor-HH3 positive 
cells were conducted using the BD FACS Canto and the 
quantitative analysis using Modfit LT software (Verity).
Statistics
All the differences in percentages of reduction of the 
cell viability were analyzed by unpaired t-test (P≤0.05 was 
considered as statistically significant).
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